Omega Flex Inc

The stock remains in a Stage 4 decline following a decisive support failure, confirming a dominant downtrend with lower highs and lower lows. Recent relief rallies have been sold into dynamic resistance, and price is currently rebounding but well below the declining 9 and 21 EMAs without signs of exhaustion. Short-term conditions remain indeterminate until price reaches the sloping EMAs. Execution should be deferred and a trim into the dynamic resistance zone around the 9 and 21 EMA is recommended.

• ↑Q2 EPS $0.27, net margin 13.6% and ROE 15.9% highlight efficiency
• ↑CE Mark for MediTrac tubing may drive medical segment growth
• ↓Significant negative growth factor implies limited future expansion